Krka Delivers On Pledge To Publish Five-Year Business Plan

R&D, Sales Growth And EBITDA Among Key Strategic Objectives

 
• By Dean Rudge

Slovenian firm Krka wishes to strengthen and optimize its vertically integrated business model over the next five years, just one of many goals just published by the company under a new business plan to 2026.

Blue Arrows Rising up in wood blocks
Krka aims to be a leader in branded generics • Source: Alamy

Attaining at least 5% average annual sales growth in terms of volume/value, allocating 10% of revenues to research and development, and achieving an average EBITDA margin of at least 25% are among a raft of key strategic objectives that Krka Group has laid out to the year 2026, following publication of its nine-month financial results and 2022 group business plan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business